Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep.
Experimental vaccine trials against hydatid disease have been undertaken in sheep using the EG95 recombinant vaccine. Challenge infection was with viable Echinococcus granulosus eggs obtained from a New Zealand isolate (dog/sheep cycle), an Australian isolate (dingo/wallaby cycle) and an Argentine isolate (dog/sheep cycle). Vaccination with EG95 conferred a high degree of protection against challenge with all three parasite isolates (protection range 96-100%). Taken together, the trials demonstrated that 86% of vaccinated sheep were completely free of viable hydatid cysts when examined approximately 1 year after challenge infection. Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns.
Lightowlers
M W
MW
Molecular Parasitology Laboratory, The University of Melbourne, Vic. Australia. marshall@unimelb.edu.au
Jensen
O
O
Fernandez
E
E
Iriarte
J A
JA
Woollard
D J
DJ
Gauci
C G
CG
Jenkins
D J
DJ
Heath
D D
DD
D000818:Animals; D000947:Antigens, Helminth / Q000276:immunology / Q000627:therapeutic use*; D001118:Argentina; D001315:Australia; D004285:Dogs; D004443:Echinococcosis / Q000276:immunology / Q000517:prevention & control / Q000635:transmission / Q000662:veterinary*; D004446:Echinococcus / Q000276:immunology; D005260:Female; D008137:Longitudinal Studies; D007614:Macropodidae / Q000469:parasitology; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D012756:Sheep; D012757:Sheep Diseases / Q000469:parasitology / Q000517:prevention & control*; D013045:Species Specificity; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
D000947:Antigens, Helminth; D014614:Vaccines, Synthetic